Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Peptic Ulcer Disease Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00255164
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Not applicable Interventional

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

NCT01733810
View directory record Official record
Conditions
Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
Cessation of Acid Suppressing Medications
Other
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 3 Interventional

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

NCT00079833
View directory record Official record
Conditions
Zollinger-Ellison Syndrome
Interventions
Esomeprazole magnesium (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Not applicable Interventional

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Proton pump inhibitor (lansoprazole)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2011 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 1, 2026, 11:08 PM EDT
Recruiting Not applicable Interventional

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585
View directory record Official record
Conditions
Acute Gastrointestinal Bleeding
Interventions
UI-EWD, Conventional therapy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational

Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)

NCT00212225
View directory record Official record
Conditions
Helicobacter Infections, Gastritis, Peptic Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 1, 2026, 11:08 PM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational

Registry for Upper Gastrointestinal Bleeding

NCT04211194
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage, Peptic Ulcer, Acute With Hemorrhage
Interventions
Upper GI Endoscopy
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
2,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

NCT00995410
View directory record Official record
Conditions
Aspirin-Associated Gastric Ulcers
Interventions
PA32540
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 2 Interventional

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

NCT00037570
View directory record Official record
Conditions
Peptic Ulcer Hemorrhage
Interventions
Pantoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC Aspirin 325
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT03060746
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Newly Diagnosed
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Mesa, Arizona • Mission Hills, California • Oxnard, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

NCT00001254
View directory record Official record
Conditions
Zollinger Ellison Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 11:08 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Diclofenac/Misoprostol
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 2 Interventional

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

NCT00001228
View directory record Official record
Conditions
Islet Cell Adenoma, Zollinger Ellison Syndrome
Interventions
Interferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 4 Interventional Results available

Ulcer Prevention Study in Post Gastric Bypass Patients

NCT00557349
View directory record Official record
Conditions
Marginal Ulcers
Interventions
Omeprazole, Famotidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 1, 2026, 11:08 PM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

NCT03060733
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Post-Therapy
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Mission Hills, California • Great Neck, New York • Mentor, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 1, 2026, 11:08 PM EDT
Completed Phase 4 Interventional

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

NCT00428701
View directory record Official record
Conditions
Gastric Ulcer
Interventions
Esomeprazole Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 1, 2026, 11:08 PM EDT